Skip to main content
. 2009 Jan;5(1):18–20. doi: 10.1200/JOP.0913001

Table 1.

Desirable Characteristics for Compendia Used As References for Off-Label Uses of Anticancer Drugs and Biologicals2(p60)

  • Extensive breadth of listings

  • Quick processing from application for inclusion to listing

  • Detailed description of the evidence reviewed for every individual listing

  • Use of pre-specified published criteria for weighing evidence

  • Use of prescribed published process for making recommendations

  • Publicly transparent process for evaluating therapies

  • Explicit “Not recommended” listing when validated evidence is appropriate

  • Explicit listing and recommendations regarding therapies, including sequential use or combination in relation to other therapies

  • Explicit “Equivocal” listing when validated evidence is equivocal

  • Process for public identification and notification of potential conflicts of interest of the compendia's parent and sibling organizations, reviewers, and committee members, with an established procedure to manage recognized conflicts